The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
MarketBeat ·